Opinion|Videos|July 10, 2024
Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
Dr Garfall, MD, provides insights following results derived from the MajesTEC-1 study.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the data you presented at the 2024 ASCO Annual Meeting on long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM).
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AI-Supported Mammography Caught More Cancers During Screening
2
Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026
3
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
4
The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine
5
